[go: up one dir, main page]

ES2058892T3 - Uso de omeprazol como agente antimicrobiano. - Google Patents

Uso de omeprazol como agente antimicrobiano.

Info

Publication number
ES2058892T3
ES2058892T3 ES90902854T ES90902854T ES2058892T3 ES 2058892 T3 ES2058892 T3 ES 2058892T3 ES 90902854 T ES90902854 T ES 90902854T ES 90902854 T ES90902854 T ES 90902854T ES 2058892 T3 ES2058892 T3 ES 2058892T3
Authority
ES
Spain
Prior art keywords
omeprazole
antimicrobial agent
metoxi
benzoimidiazole
campilobacter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90902854T
Other languages
English (en)
Inventor
Masaaki - - - Nishi-Iwat Tomoi
Yoshifumi - Oaza-Nakasoi Ikeda
Yoshiko - Wakazono-Cho Yokota
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hassle AB
Original Assignee
Hassle AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=12300238&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2058892(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hassle AB filed Critical Hassle AB
Application granted granted Critical
Publication of ES2058892T3 publication Critical patent/ES2058892T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

USO DE 5-METOXI-2-[[(4-METOXI-3,5-DIMETIL-2-PIRIDINILO) METILO]-1H-BENZOIMIDIAZOL O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE EL EN EL TRATAMIENTO DE ENFERMEDADES INFECCIOSAS, ESPECIALES EN AQUELLAS CAUSADAS POR "CAMPILOBACTER PILORI".
ES90902854T 1989-02-09 1990-02-02 Uso de omeprazol como agente antimicrobiano. Expired - Lifetime ES2058892T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1030311A JP2694361B2 (ja) 1989-02-09 1989-02-09 抗菌剤

Publications (1)

Publication Number Publication Date
ES2058892T3 true ES2058892T3 (es) 1994-11-01

Family

ID=12300238

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90902854T Expired - Lifetime ES2058892T3 (es) 1989-02-09 1990-02-02 Uso de omeprazol como agente antimicrobiano.

Country Status (19)

Country Link
US (1) US5093342A (es)
EP (1) EP0414847B1 (es)
JP (1) JP2694361B2 (es)
KR (1) KR0140236B1 (es)
AT (1) ATE94063T1 (es)
AU (1) AU626641B2 (es)
CA (1) CA2025668C (es)
CY (1) CY1909A (es)
DE (1) DE69003207T2 (es)
DK (1) DK0414847T3 (es)
ES (1) ES2058892T3 (es)
HK (1) HK52196A (es)
HU (1) HU205253B (es)
IE (1) IE65814B1 (es)
IL (1) IL93263A0 (es)
LV (1) LV10577B (es)
MY (1) MY111737A (es)
PH (1) PH26787A (es)
WO (1) WO1990009175A1 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0382489T3 (da) * 1989-02-10 1995-01-16 Takeda Chemical Industries Ltd Monoklonalt anti-humant papillomvirusantistof, hybridomcelle, der producerer dette, samt fremgangsmåde til fremstilling deraf
GB9018603D0 (en) * 1990-08-24 1990-10-10 Smith Kline French Lab Compositions
WO1992004898A1 (de) * 1990-09-14 1992-04-02 Byk Gulden Lomberg Chemische Fabrik Gmbh Verwendung von pyridylmethylsulfinyl-1h-benzimidazol derivaten zur behandlung durch helicobacter verursachten erkrankungen
IS3990A (is) * 1992-04-24 1993-10-25 Ab Astra Aðferð við að blanda saman efni sem hindrar flæðimagasýru og bakteríueyðandi efnis sem brotnar niður í súru umhverfi
US5504082A (en) * 1992-06-01 1996-04-02 Yoshitomi Pharmaceutical Industries, Ltd. Pyridine compound and pharmaceutical compostions
EP0673246A1 (de) * 1992-12-10 1995-09-27 Byk Gulden Lomberg Chemische Fabrik GmbH Verwendung von alkylthiopyridinen zur bekämpfung von heliobacter-bakterien
US5834002A (en) * 1994-05-02 1998-11-10 Josman Laboratories, Inc. Chewing gum containing colloidal bismuth subcitrate
US6902738B2 (en) * 1994-05-02 2005-06-07 Josman Laboratories, Inc. Topical oral dosage forms containing bismuth compounds
US6426085B1 (en) 1994-05-02 2002-07-30 Josman Laboratories Inc. Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis
US6379651B1 (en) 1995-02-07 2002-04-30 Josman Laboratories Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases
WO1996024342A1 (en) * 1995-02-07 1996-08-15 Narayan Krishnarao Athanikar Concomitant treatment with oral bismuth compounds
US6372784B1 (en) 1995-02-07 2002-04-16 Josman Laboratories, Inc. Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
EP1037634B1 (en) * 1997-12-08 2005-09-07 ALTANA Pharma AG Oral administration form comprising a proton pump inhibitor (e.g.pantoprazole)
US6861448B2 (en) * 1998-01-14 2005-03-01 Virtual Drug Development, Inc. NAD synthetase inhibitors and uses thereof
AU2031799A (en) 1998-01-14 1999-08-02 Uab Research Foundation, The Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6787342B2 (en) 2000-02-16 2004-09-07 Merial Limited Paste formulations
SE0002476D0 (sv) 2000-06-30 2000-06-30 Astrazeneca Ab New compounds
US20030129186A1 (en) 2001-07-25 2003-07-10 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
EP1469839A2 (en) * 2002-01-25 2004-10-27 Santarus, Inc. Transmucosal delivery of proton pump inhibitors
TWI367759B (en) * 2003-02-20 2012-07-11 Santarus Inc A novel formulation, omeprazole antacid complex-immediate release, for rapid and sustained suppression of gastric acid
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AU2004257864A1 (en) * 2003-07-18 2005-01-27 Santarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
EP1648416A4 (en) * 2003-07-18 2012-03-28 Santarus Inc PHARMACEUTICAL FORMULATIONS FOR INHIBITING THE ACIDIC ACIDIFICATION AND MANUFACTURING AND USE METHOD
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2008539047A (ja) 2005-04-28 2008-11-13 プロテウス バイオメディカル インコーポレイテッド ファーマインフォーマティックスシステム
AU2007225935B2 (en) 2006-03-10 2011-12-22 Link Genomics, Inc. Novel pyridine derivative having anti-Helicobacter pylori activity
MX2009002893A (es) 2006-09-18 2009-07-10 Raptor Pharmaceutical Inc Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap).
WO2008067037A2 (en) 2006-10-05 2008-06-05 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
WO2008057802A2 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
CA2671949C (en) 2006-12-18 2011-11-01 Arigen Pharmaceuticals, Inc. Helicobacter pylori eradicating agent having inhibitory activity on gastric acid secretion
CN102316902B (zh) 2009-02-20 2014-09-24 to-BBB控股股份有限公司 基于谷胱甘肽的药物递送系统
AU2010235726B2 (en) 2009-04-09 2012-01-19 Link Genomics, Inc. Pyridine thio derivative, and pharmaceutical composition which contains same and has anti-Helicobacter pylori action
KR101909711B1 (ko) 2009-05-06 2018-12-19 라보라토리 스킨 케어, 인크. 활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
US8722026B2 (en) 2010-01-06 2014-05-13 Elc Management, Llc Skin lightening compositions
US8992897B2 (en) 2010-01-06 2015-03-31 Elc Management Llc Skin lightening compositions
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
KR101628474B1 (ko) * 2014-08-27 2016-06-08 경북대학교 산학협력단 오메프라졸을 유효성분으로 포함하는 피부 미백용 화장료 조성물
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4359465A (en) * 1980-07-28 1982-11-16 The Upjohn Company Methods for treating gastrointestinal inflammation
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
HU886738D0 (en) * 1987-10-30 1990-02-28 Haessle Ab Process for the preparation of pharmaceutical compositions against osteoporosis containing 2-pyridinyl-methyl-(sulfinyl or thio)-benzimidazoles

Also Published As

Publication number Publication date
MY111737A (en) 2000-12-30
DE69003207T2 (de) 1994-02-03
WO1990009175A1 (en) 1990-08-23
AU626641B2 (en) 1992-08-06
IL93263A0 (en) 1990-11-29
HUT54890A (en) 1991-04-29
CA2025668C (en) 1998-09-15
DK0414847T3 (da) 1993-12-13
LV10577A (lv) 1995-04-20
KR910700048A (ko) 1991-03-13
JP2694361B2 (ja) 1997-12-24
CY1909A (en) 1990-02-02
HU901539D0 (en) 1991-02-28
IE900418L (en) 1990-08-09
HU205253B (en) 1992-04-28
ATE94063T1 (de) 1993-09-15
CA2025668A1 (en) 1990-08-10
EP0414847A1 (en) 1991-03-06
JPH02209809A (ja) 1990-08-21
AU5038190A (en) 1990-09-05
PH26787A (en) 1992-10-13
LV10577B (en) 1995-10-20
KR0140236B1 (ko) 1998-06-01
EP0414847B1 (en) 1993-09-08
DE69003207D1 (de) 1993-10-14
HK52196A (en) 1996-03-29
US5093342A (en) 1992-03-03
IE65814B1 (en) 1995-11-15

Similar Documents

Publication Publication Date Title
ES2058892T3 (es) Uso de omeprazol como agente antimicrobiano.
EP0509317A3 (en) Use of droloxifene in the treatment of bone diseases
NO932650D0 (no) Forbedringer vedroerende benzotiofener
ES2159591T3 (es) Composicion de liberacion controlada.
TW234691B (es)
FI956014L (fi) Nona- ja dekapeptidien käyttö lääkkeen valmistamiseksi AIDS-sairauden hoitoon
ES2130114T3 (es) 5,11-dihidro-6h-dipirido(3,2-b:2',3'-e)(1,4)diazepinas y su uso en la prevencion o tratamiento de infeccion por hiv.
FI910903L (fi) Poroest keramiskt kropp.
ITRM920412A1 (it) Eteroprostanoidi, procedimento per la loro preparazione e loro impiego terapeutico.
CL2008003939A1 (es) Uso de escitalopram o una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento de ansiedad social (divisional de la solicitud 1799-00).
ES2191075T3 (es) 8-arilalquil- y 8-arilheteroalquil-5,11-dihidro-6h-dipirido-(3,2-b:2',3'-e)(1,4)diazepinas y su uso en la prevencion o tratamiento de infecciones por hiv.
EP0328924A3 (en) Thienotriazolodiazepine compounds and pharmaceutical uses thereof
FI922054L (fi) Sjukhusdesinfektionsvagn.
ITRM930488A0 (it) Composizione detergente per la cura del corpo.
IT1318365B1 (it) Dispositivo di protezione per l'ago per siringa ad uso medicale.
ES2191908T3 (es) 4-aminopirrol(3,2-d)pirimidinas como antagonistas del receptor del neuropeptido.
AP9400647A0 (en) Medicaments for use in treatment of HIV or cancer patients.
AU3401093A (en) Therapeutic agent for threatened abortion
AU2880595A (en) Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
DE69426021D1 (de) Xamonelin-Tartrat
ES2070148T3 (es) Derivado de la glicerina y utilizacion farmacologica del mismo.
FI965196A7 (fi) HIV-infektion yhdistelmähoito
MX9203221A (es) Compuesto farmacologicamente activo, preparacion y empleo.
SE9602262D0 (sv) New use of derivatives of cystine
FI910110A0 (fi) I en individuell steril foerpackning foerpackad naol och foer engaongsbruk avsedd spruta med dylik naol.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 414847

Country of ref document: ES